JMP reiterates St. Jude at strong buy

St. Jude Medical, Inc. was reiterated by JMP Securities analyst Robert C. Faulkner at a strong buy as outlook cuts to competitor Guidant Corp.'s ICD and CRM markets translate into a potential upside for St. Jude, JMP said. The stock is JMP's No. 1 pick going into the new year. Shares of the St. Paul, Minn., maker of cardiovascular devices were up 4 cents, or 0.80%, at $50.54 on volume of 1,379,100 shares versus the three-month running average of 2,049,380 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.